MENLO PARK, CA, USA and SHANGHAI, CHINA, September 10th, 2013 ， IncellDx announced that it has executed an Exclusive Distribution Agreement with Centre Testing International Corporation (NG28), the largest product conformity testing corporation in China and a public company on the Shenzhen Stock Exchange, Shenzhen, China, to distribute to Chinese laboratories, hospitals and healthcare service providers IncellDx’s proprietary laboratory test for the detection and quantification of oncogenic HPV E6, E7 mRNA in China. According to IncellDx, it believes that this agreement will greatly augment its business presence in Asia.
This IncellDx test is based upon IncellDx's advanced molecular diagnostic technology for quantifying specific biomarkers that have been associated with an increased risk of progression to cervical cancer, and will greatly improve Chinese physicians, hospitals and healthcare providers ability to manage Chinese women at risk of developing cervical cancer.
Measuring the potential oncogenic activity of the human papillomavirus (HPV) in infected cervical cells, this novel technology functions by detecting and quantifying the expression of viral oncogenes responsible for triggering progression to cervical cancer, resulting in a higher specificity that existing tests now being used in China lack.
"We are pleased that IncellDx has selected NG28 to exclusively distribute this advanced innovative molecular diagnostic test to Chinese laboratories and health care providers so that they can use it to improve treatment and avoid unnecessary worry or surgical procedures for Chinese women diagnosed with HPV. The IncellDx test will be distributed by NG28 BioDiagnostics (NG28B) a sub-company of NG28. We established NG28B to provide leading edge molecular diagnostic products and services to the China healthcare market.” said Sangem Hsu, President of NG28.
Bruce K. Patterson MD, founder and CEO of IncellDx, commented, "The high level of specificity our technology produces not only has a significant, positive economic impact on healthcare delivery costs by potentially reducing the number of unnecessary colposcopy/biopsies, but additionally improves patient care by eliminating unnecessary concerns associated with some current results. We are pleased that our partnership with NG28 will provide better healthcare outcomes for women in China."
About Center Testing International Corp. and NG28 BioDiagnostics
NG28 BioDiagnostics or NG28B is a sub-company of Centre Testing International (NG28) specializing in the registration and distribution of molecular diagnostic products, technologies and services in China. NG28 is the largest Chinese product conformity testing corporation in China and a public company on the Shenzhen Stock Exchange, Shenzhen, China. NG28 operates more than 30 branches in mainland China. NG28 also has branches in Taiwan, Hong Kong, Singapore, the UK, Ireland and North America.
About IncellDx, Inc.
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more information, please visit www.incelldx.com.
Tara Mackay - Investor Relations Coordinator
201-791-2600 x8750
In China: For information or to order the IncellDx HPV E6, E7 mRNA test, please contact Angela Zheng, Technical Manager of NG28B at +86-755-33681088 or +86-21-61431361.
粤公网安备 44030602000441号 